The Toronto Stock Exchange reports that Theratechnologies Inc. will be delisted at the close on Sept. 26, 2025. According to the TSX, CB Biotechnology LLC, an affiliate of Future Pak LLC, has acquired all of the issued and outstanding shares of the company, pursuant to a statutory plan of arrangement under Chapter XVI –- Division II of the Business Corporations Act (Quebec).

Shareholders of Theratechnologies will receive, per share held, $3.01 (U.S.) in cash and one contingency value right (CVR) to be issued by the purchaser, less any applicable withholdings. Each CVR will entitle the holder thereof to aggregate payments from the purchaser of up to $1.19 (U.S.) per CVR, subject to the CVR agreement and if the CVR milestones set out in the CVR agreement are achieved by the company. To receive the consideration, Theratechnologies shareholders must return the letter of transmittal together with certificates and/or DRS advices representing shares to Computershare Investor Services Inc. at its principal offices in Toronto.

For more information, see the company's management proxy circular dated Aug. 12, 2025, available on SEDAR+.